PriceTargets.com logo

NASDAQ:ATOS - Atossa Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 151.68 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.98 As of 01/25/2021 01:00 AM ET
▲ +1.11 (59.36%)
1 month | 3 months | 12 months
Get New Atossa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATOS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.50
▲ +151.68% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 151.68% upside from the last price of $2.98.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Atossa Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/18/2020Maxim GroupReiterated RatingBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
9/17/2020Ascendiant Capital MarketsInitiated CoverageBuy$7.00High
i
7/31/2020Maxim GroupReiterated RatingBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
7/17/2020Maxim GroupBoost Price Target$4.00 ➝ $8.00High
i
Rating by Jason McCarthy at Maxim Group
7/16/2020Maxim GroupReiterated RatingPositiveHigh
i
Rating by Jason McCarthy at Maxim Group
5/23/2020Maxim GroupInitiated CoverageBuy$4.00Low
i
Rating by Jason McCarthy at Maxim Group
4/28/2020Maxim GroupInitiated CoverageBuy$4.00Low
i
Rating by Jason McCarthy at Maxim Group
4/17/2020Maxim GroupReiterated RatingBuy$4.00Low
i
Rating by Jason McCarthy at Maxim Group
12/18/2019Maxim GroupUpgradeHold ➝ BuyHigh
i
Rating by Jason McCarthy at Maxim Group
6/27/2019Maxim GroupDowngradeBuy ➝ HoldLow
i
Rating by Jason McCarthy at Maxim Group
3/26/2019Maxim GroupReiterated RatingBuy$9.00High
i
Rating by Jason McCarthy at Maxim Group
1/9/2019Maxim GroupReiterated RatingBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
12/3/2018Maxim GroupSet Price TargetBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
11/14/2018Maxim GroupReiterated RatingBuy$5.00Medium
i
10/11/2018Maxim GroupReiterated RatingBuy$7.00Low
i
Rating by Jason McCarthy at Maxim Group
7/18/2018Maxim GroupReiterated Rating$2.47$10.00Low
i
Rating by Jason McCarthy at Maxim Group
6/26/2018Maxim GroupReiterated RatingBuy$10.00Low
i
Rating by Jason McCarthy at Maxim Group
5/15/2018Noble FinancialSet Price TargetBuy$10.00High
i
Rating by Caroline Palomeque at Noble Financial
5/14/2018Maxim GroupSet Price TargetBuy$10.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/3/2018Maxim GroupSet Price TargetBuy$10.00Low
i
Rating by Jason McCarthy at Maxim Group
1/26/2018Maxim GroupInitiated CoverageBuy ➝ Buy$24.00High
i
(Data available from 1/25/2016 forward)
Atossa Therapeutics logo
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.98
$2.01
$3.00

50 Day Range

MA: $1.08
$0.85
$1.87

52 Week Range

Now: $2.98
$0.76
$5.08

Volume

91,583,729 shs

Average Volume

29,310,313 shs

Market Capitalization

$212.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Atossa Therapeutics?

The following Wall Street research analysts have issued stock ratings on Atossa Therapeutics in the last year: Ascendiant Capital Markets, and Maxim Group.

What is the current price target for Atossa Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Atossa Therapeutics in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 151.7%. Maxim Group has the highest price target set, predicting ATOS will reach $8.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $7.00 for Atossa Therapeutics in the next year.

What is the current consensus analyst rating for Atossa Therapeutics?

Atossa Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATOS will outperform the market and that investors should add to their positions of Atossa Therapeutics.

What other companies compete with Atossa Therapeutics?

Other companies that are similar to Atossa Therapeutics include Collegium Pharmaceutical, Avid Bioservices, Odonate Therapeutics, Foghorn Therapeutics, Provention Bio, G1 Therapeutics, Gossamer Bio, Esperion Therapeutics, VBI Vaccines, Vanda Pharmaceuticals, ZIOPHARM Oncology, Calliditas Therapeutics AB (publ), Evelo Biosciences, Aclaris Therapeutics and Dynavax Technologies.

How do I contact Atossa Therapeutics' investor relations team?

Atossa Therapeutics' physical mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company's listed phone number is 206-325-6086 and its investor relations email address is [email protected] The official website for Atossa Therapeutics is www.atossagenetics.com.